Rod-cone dystrophy describes a specific sequence of retinal degeneration: the rod photoreceptors, responsible for vision in dim light, deteriorate first, and only later do the cone photoreceptors — responsible for daylight and colour vision — become significantly involved. This sequencing is what places most classic cases of retinitis pigmentosa under the rod-cone dystrophy label, and it is clinically important because it predicts the order in which symptoms will appear.
For Somali patients referred with this specific terminology on a prior report, understanding the rod-first pattern helps set realistic expectations about which visual functions are likely to be affected earliest and which are likely to be preserved for longer.

Associate Professor, Vitreo-Retina Surgeon. 10+ Years Experience

Senior Consultant Ophthalmologist & Eye Surgeon· 26+ yrs experience

Consultant Ophthalmologist & Eye Surgeon, MD, DO .16+ Years Experience
Care planning follows the same regenerative and supportive framework used for other progressive photoreceptor dystrophies — stem cell therapy is evaluated as a means of supporting remaining retinal function where testing indicates the patient is a reasonable candidate, alongside practical guidance on adapting to reduced night and peripheral vision while central vision remains comparatively stable.
“The terms overlap substantially. ‘Rod-cone dystrophy’ describes the pattern in which the disease progresses — rods affected before cones — and this pattern applies to the large majority of what is clinically called retinitis pigmentosa.”
”
The order of photoreceptor involvement is reversed. In rod-cone dystrophy, night vision and peripheral vision decline first while central and colour vision are preserved longer; in cone-rod dystrophy, central vision and colour perception are typically affected earlier, with peripheral and night vision more preserved initially.”
“In many rod-cone dystrophies, central vision can decline in later stages once the disease progresses to involve the cone photoreceptors, though the timeline varies widely between individuals and depends heavily on the underlying genetic cause.”
“This is decided case by case after the initial evaluation, based on the rate of change seen in your ERG and visual field results. Some patients are monitored annually, while others with a more stable pattern may be reviewed less frequently.”
